- Home
- COLL vs PSEC Comparison
COLL vs PSEC Comparison
Compare COLL & PSEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COLL | PSEC |
|---|---|---|
| Founded | 2002 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.2B |
| IPO Year | 2015 | 2004 |
Fundamental Metrics
Financial Performance| Metric | COLL | PSEC |
|---|---|---|
| Price | $48.66 | $2.75 |
| Analyst Decision | Strong Buy | Sell |
| Analyst Count | 6 | 1 |
| Target Price | ★ $47.50 | $2.50 |
| AVG Volume (30 Days) | 494.7K | ★ 4.6M |
| Earning Date | 02-26-2026 | 02-09-2026 |
| Dividend Yield | N/A | ★ 19.93% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.63 | N/A |
| Revenue | ★ $757,067,000.00 | $680,752,000.00 |
| Revenue This Year | $26.35 | N/A |
| Revenue Next Year | $3.67 | N/A |
| P/E Ratio | $29.06 | ★ N/A |
| Revenue Growth | ★ 26.34 | N/A |
| 52 Week Low | $23.23 | $2.45 |
| 52 Week High | $50.79 | $4.47 |
Technical Indicators
Market Signals| Indicator | COLL | PSEC |
|---|---|---|
| Relative Strength Index (RSI) | 58.37 | 66.17 |
| Support Level | $44.51 | $2.66 |
| Resistance Level | $50.79 | $2.76 |
| Average True Range (ATR) | 1.45 | 0.08 |
| MACD | -0.40 | 0.03 |
| Stochastic Oscillator | 63.89 | 91.89 |
Price Performance
Historical ComparisonAbout COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
About PSEC Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests mainly in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.